Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARK C CASCIONE

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1447249115
CMS profile
20399
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$343,077.55

627 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 13 of 13; records 601–627 of 627 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARK C CASCIONE

NPI 1447249115 · CMS profile ID 20399

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 13 of 13; records 601–627 of 627 matching records. This page contains 27 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447249115?year=2019&recipient=provider&page=13#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARK C CASCIONE, NPI 1447249115, CMS profile ID 20399. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 13 of 13; records 601–627 of 627 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447249115?year=2019&recipient=provider&page=13#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MARK C CASCIONE, NPI 1447249115, CMS profile ID 20399. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 13 of 13; records 601–627 of 627 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447249115?year=2019&recipient=provider&page=13#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MARK C CASCIONE, NPI 1447249115, CMS profile ID 20399, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 13 of 13; records 601–627 of 627 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1447249115?year=2019&recipient=provider&page=13#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

627 matching records · $343,077.55 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 627 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 601–627 of 627.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $13.4901/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681291245 CMS
Bayer HealthCare Pharmaceuticals Inc. $17.2101/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628426475 CMS
Zyla Life Sciences $13.6301/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704864385 CMS
GENZYME CORPORATION $454.5201/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694224063 CMS
GENZYME CORPORATION $238.0001/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694224065 CMS
GENZYME CORPORATION $50.1701/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694224067 CMS
GENZYME CORPORATION $34.3701/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694224069 CMS
GENZYME CORPORATION $73.3201/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694224071 CMS
GENZYME CORPORATION $51.3201/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694224073 CMS
GENZYME CORPORATION $11,760.0001/18/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694224075 CMS
GENZYME CORPORATION $44.5001/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694224077 CMS
GENZYME CORPORATION $228.7501/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694318161 CMS
GENZYME CORPORATION $15.3001/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694318163 CMS
Sunovion Pharmaceuticals Inc. $2.4301/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692482265 CMS
Novartis Pharmaceuticals Corporation $12.0401/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659044649 CMS
Supernus Pharmaceuticals, Inc. $12.5101/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702291117 CMS
GENZYME CORPORATION $17.3701/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694276129 CMS
Amgen Inc. $16.1001/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662714291 CMS
Supernus Pharmaceuticals, Inc. $11.1101/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702291115 CMS
UCB, Inc. $10.6201/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688253747 CMS
Biogen, Inc. $21.0101/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660641565 CMS
Novartis Pharmaceuticals Corporation $9.1801/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658808057 CMS
Adamas Pharmaceuticals, Inc. $14.6301/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694962067 CMS
Genentech USA, Inc. $16.9801/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681207396 CMS
Allergan Inc. $19.9701/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670169443 CMS
Teva Pharmaceuticals USA, Inc. $9.7101/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697764571 CMS
Teva Pharmaceuticals USA, Inc. $6.7001/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697780741 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $343,077.55 627
PY2020 $85,787.95 402
PY2021 $143,685.54 502
PY2022 $221,127.61 524
PY2023 $171,367.63 433
PY2024 $132,504.28 405
PY2025 $115,505.87 380

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,151,825.65 69
PY2024 Recipient $468.35 4
PY2024 Principal investigator $2,197,302.12 48
PY2023 Recipient $8,289.33 1
PY2023 Principal investigator $1,273,906.94 71
PY2022 Principal investigator $2,399,257.52 23
PY2021 Principal investigator $1,287,547.34 43
PY2020 Principal investigator $1,151,050.13 44
PY2019 Recipient $2,356.25 1
PY2019 Principal investigator $490,316.87 47

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

69 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $585.00 11/24/2025 Non-covered Recipient Entity
Axiom Brain Health Llc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226087921
Principal investigator 1 Novartis Pharmaceuticals Corporation $20.93 10/27/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190307601
Principal investigator 1 GENZYME CORPORATION $90.00 10/20/2025 Non-covered Recipient Entity
Axiom Brain Health Llc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226087811
Principal investigator 1 GENZYME CORPORATION $10,310.00 10/20/2025 Non-covered Recipient Entity
Axiom Brain Health Llc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226087822
Principal investigator 1 Roche Products Limited $302.24 09/25/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576890
Principal investigator 1 Roche Products Limited $302.24 09/25/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576892
Principal investigator 1 Roche Products Limited $302.24 09/25/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576896
Principal investigator 1 Roche Products Limited $181.52 09/25/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576900
Principal investigator 1 Roche Products Limited $302.24 09/25/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576904
Principal investigator 1 Roche Products Limited $302.24 09/25/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576908
Principal investigator 1 Roche Products Limited $302.24 09/25/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576912
Principal investigator 1 GENZYME CORPORATION $195.00 09/03/2025 Non-covered Recipient Entity
Axiom Brain Health Llc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226087737
Principal investigator 1 Novartis Pharmaceuticals Corporation $23,273.75 08/25/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension No dispute reported 06/30/2026 1190298447
Principal investigator 1 Novartis Pharmaceuticals Corporation $276.00 08/18/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate or Fingolimod Therapy No dispute reported 06/30/2026 1190298451
Principal investigator 1 GENZYME CORPORATION $26,360.00 08/11/2025 Non-covered Recipient Entity
Axiom Brain Health Llc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226087693
Principal investigator 1 GENZYME CORPORATION $1,325.00 08/04/2025 Non-covered Recipient Entity
Axiom Brain Health Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226087669
Principal investigator 1 GENZYME CORPORATION $10,310.00 07/14/2025 Non-covered Recipient Entity
Axiom Brain Health Llc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226087652
Principal investigator 1 GENZYME CORPORATION $950.00 06/27/2025 Non-covered Recipient Entity
Axiom Clinical Research Of Florida
A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1226101106
Principal investigator 1 GENZYME CORPORATION $811.80 06/27/2025 Non-covered Recipient Entity
Axiom Clinical Research Of Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226101111
Principal investigator 1 Roche Products Limited $302.24 06/24/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576768
Principal investigator 1 Roche Products Limited $302.24 06/24/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576776
Principal investigator 1 Roche Products Limited $302.24 06/24/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576784
Principal investigator 1 Roche Products Limited $302.24 06/24/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576788
Principal investigator 1 Roche Products Limited $302.24 06/24/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576818
Principal investigator 1 Roche Products Limited $302.24 06/24/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576841
Principal investigator 1 Roche Products Limited $302.24 06/24/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576844
Principal investigator 1 Roche Products Limited $302.24 06/24/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576853
Principal investigator 1 Roche Products Limited $302.24 06/24/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576861
Principal investigator 1 Roche Products Limited $302.24 06/24/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576873
Principal investigator 1 Roche Products Limited $302.24 06/24/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576877
Principal investigator 1 Roche Products Limited $302.24 06/24/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576882
Principal investigator 1 GENZYME CORPORATION $3,880.00 06/11/2025 Non-covered Recipient Entity
Axiom Clinical Research Of Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226101101
Principal investigator 1 GENZYME CORPORATION $950.00 05/12/2025 Non-covered Recipient Entity
Axiom Clinical Research Of Florida Inc
A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1226145300
Principal investigator 1 Roche Products Limited $302.24 05/07/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576772
Principal investigator 1 Roche Products Limited $302.24 05/07/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576780
Principal investigator 1 Roche Products Limited $302.24 05/07/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576792
Principal investigator 1 Roche Products Limited $302.24 05/07/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576797
Principal investigator 1 Roche Products Limited $302.24 05/07/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576802
Principal investigator 1 Roche Products Limited $302.24 05/07/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576806
Principal investigator 1 Roche Products Limited $302.24 05/07/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576810
Principal investigator 1 Roche Products Limited $302.24 05/07/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576813
Principal investigator 1 Roche Products Limited $302.24 05/07/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576822
Principal investigator 1 Roche Products Limited $302.24 05/07/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576825
Principal investigator 1 Roche Products Limited $302.24 05/07/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576829
Principal investigator 1 Roche Products Limited $302.24 05/07/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576834
Principal investigator 1 Roche Products Limited $302.24 05/07/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576838
Principal investigator 1 Roche Products Limited $302.24 05/07/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576849
Principal investigator 1 Roche Products Limited $302.24 05/07/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576857
Principal investigator 1 Roche Products Limited $302.24 05/07/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576865
Principal investigator 1 Roche Products Limited $302.24 05/07/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576869
Principal investigator 1 Roche Products Limited $302.24 05/07/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576886
Principal investigator 1 GENZYME CORPORATION $868.00 04/04/2025 Non-covered Recipient Entity
Axiom Clinical Research Of Florida
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226101057
Principal investigator 1 GENZYME CORPORATION $4,631.00 03/28/2025 Non-covered Recipient Entity
Axiom Clinical Research Of Florida
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226101050
Principal investigator 1 GENZYME CORPORATION $765.00 03/10/2025 Non-covered Recipient Entity
Axiom Clinical Research Of Florida
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226101043
Principal investigator 1 Novartis Pharmaceuticals Corporation $462,542.11 02/28/2025 Non-covered Recipient Entity
AXIOM BRAIN HEALTH LLC
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190312941
Principal investigator 1 GENZYME CORPORATION $4,783.50 02/27/2025 Non-covered Recipient Entity
Axiom Clinical Research Of Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226101032
Principal investigator 1 Novartis Pharmaceuticals Corporation $17,058.00 02/25/2025 Non-covered Recipient Entity
AXIOM BRAIN HEALTH LLC
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190312937
Principal investigator 1 Novartis Pharmaceuticals Corporation $38,302.25 02/18/2025 Non-covered Recipient Entity
AXIOM BRAIN HEALTH LLC
A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension No dispute reported 06/30/2026 1190312933
Principal investigator 1 Novartis Pharmaceuticals Corporation $68.40 01/31/2025 Non-covered Recipient Entity
AXIOM BRAIN HEALTH
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190307133
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,102.48 01/31/2025 Non-covered Recipient Entity
AXIOM BRAIN HEALTH LLC
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190312939
Principal investigator 1 Novartis Pharmaceuticals Corporation $21,907.26 01/28/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190298455
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,500.00 01/16/2025 Non-covered Recipient Entity
AXIOM BRAIN HEALTH LLC
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190312935
Principal investigator 1 GENZYME CORPORATION $14,156.00 01/10/2025 Non-covered Recipient Entity
Axiom Clinical Research Of Florida
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226101021
Principal investigator 1 GENZYME CORPORATION $12,500.00 01/10/2025 Non-covered Recipient Entity
Axiom Clinical Research Of Florida
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226101026
Principal investigator 1 Roche Products Limited $302.24 01/09/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576754
Principal investigator 1 Roche Products Limited $302.24 01/09/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576758
Principal investigator 1 Roche Products Limited $302.24 01/09/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211576762
Principal investigator 1 Novartis Pharmaceuticals Corporation $400,988.66 01/01/2025 Non-covered Recipient Entity
AXIOM BRAIN HEALTH
A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension No dispute reported 06/30/2026 1190307131
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,075,346.63 01/01/2025 Non-covered Recipient Entity
AXIOM CLINICAL RESEARCH OF FLORIDA
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190307603